Lipocine Inc./$LPCN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
- Ticker
- $LPCN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 14
- Headquarters
- Salt Lake City, United States
- Website
- www.lipocine.com
Lipocine Inc. Metrics
BasicAdvanced
$13M
-
-$1.29
-
-
Price and volume
Market cap
$13M
52-week high
$12.37
52-week low
$1.36
Average daily volume
3.9M
Financial strength
Current ratio
11.361
Quick ratio
10.988
Profitability
EBITDA (TTM)
-10.017
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-249.16%
Operating margin (TTM)
-269.05%
Effective tax rate (TTM)
-0.00%
Revenue per employee (TTM)
$270,000
Management effectiveness
Return on assets (TTM)
-32.07%
Return on equity (TTM)
-52.86%
Valuation
Price to revenue (TTM)
3.073
Price to book
0.62
Price to tangible book (TTM)
0.62
Growth
Revenue change (TTM)
-13.37%
Earnings per share change (TTM)
26.69%
3-year revenue growth (CAGR)
6.88%
3-year earnings per share growth (CAGR)
-25.68%
10-year earnings per share growth (CAGR)
-23.68%
Lipocine Inc. Financial Performance
Revenues and expenses
Lipocine Inc. Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.